ArticleInternational journal of surgery case reports2026
Eight-year patient survival following multidisciplinary management for two recurrences of esophageal cancer: case report and literature review.
Article in International journal of surgery case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction and importance: Esophageal cancer (EC) is a malignant gastrointestinal cancer with a high rate of recurrence and metastasis. The standard treatment for primary EC is surgery, chemotherapy, radiotherapy (RT), or their combination. However, no standard treatment has yet been established for EC recurrence. Case presentation: A 64-year-old man with unresectable EC underwent chemoradiotherapy followed by surgery. Two subsequent recurrences were treated with multidisciplinary management combining surgery, chemotherapy, and RT, resulting in curative treatment. Currently, the patient continues to receive paclitaxel chemotherapy as an outpatient, with no third recurrence detected on imaging. Clinical discussion: Although EC is a malignant disease with a high recurrence rate after curative treatment, systematic treatment methods for recurrence are lacking. While surgery improves prognosis in cases of local recurrence in the lungs or lymph nodes, its effectiveness in other organ recurrences has not yet been proven. In cases of rare recurrence sites, such as the ribs or muscles, disease control has been achieved through multidisciplinary treatment. Conclusion: Multidisciplinary treatment for two recurrences of EC has achieved disease control and long-term survival. This strategy may be an effective option for managing EC recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.